India’s Contract Research, Development, and Manufacturing Organization (CRDMO) sector is projected to expand from $3–3.5 billion to $22–25 billion by 2035, driven by global pharmaceutical realignments and cost advantages. A report by BCG highlighted strengths in small molecule manufacturing, along with emerging capabilities in biologics, antibody-drug conjugates (ADCs) and gene therapies.